Discover tools and support for starting, prescribing, and treating patients with YUVIWEL
An overview of starting patients on YUVIWEL, as well as dosing and administration.
Watch full Instructions for Use video.
Learn how to reconstitute and administer YUVIWEL and more.
Access the full Prescribing Information for YUVIWEL.
The first step toward one-on-one support for your patients is completing the enrollment form.
Fill out the form below and check the box to connect with your local sales representative.
Interested in learning more about YUVIWEL for your patients with achondroplasia?
Please fill out the form below for updates and resources.
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.
The most common adverse reactions (≥5%) are vomiting, injection site reaction, pain in extremity, and nausea.
There are no available data on the use of YUVIWEL in pregnant women, or data on the presence of YUVIWEL in human milk, the potential effects on milk production or the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YUVIWEL and any potential adverse effects on the breastfed infant from YUVIWEL or from the underlying maternal condition.
YUVIWEL is not recommended for patients with moderate or severe renal impairment.
You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.
Please see full Prescribing Information for YUVIWEL.
FDA=Food and Drug Administration.